Venture Capital Firm Partner: 'There's No Better Time To Do Drug Discovery' For Cancer Treatments

Young biotech companies that find there are many costs associated with the extensive research needed to test new drugs often look to venture capital firms, like Third Rock Ventures in Boston, to fund their innovations.

One of the firm's partners, Dr. Bob Tepper, joined Morning Edition to talk about why investors would choose to put their money in cancer research despite the high risk of failure.

Correction: An earlier version of this post misstated Tepper's role in Third Rock Ventures.